Migraine
Biohaven Announces NURTEC® ODT Receives First Global Approval Outside the U.S. For Prevention of Migraine
Biohaven
PR-M12-21-01Dec 13, 2021
Biohaven to Advance Vazegepant Into Phase 3 for Acute Migraine Treatment
Biohaven
PA1632Mar 27, 2020
FDA Approval
Allergan Receives FDA Approval for Migraine Treatment
Allergan, plc
PR-M01-20-NI-001Jan 02, 2020
Clinical Results
Biohaven Achieves Positive Topline Results for Intranasal Migraine Treatment
Biohaven
PR-M12-19-NI-025Dec 17, 2019
Drug Development
Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M11-19-NI-004Nov 12, 2019
Migraine Therapy
Mimicking Environmental Enrichment for Migraine Therapy
Yuan Zhang, Ph.D.
Seurat Therapeutics
PAP-Q3-19-CL-026Oct 28, 2019
FDA Approval
FDA Approves New Treatment for Patients with Migraine
U.S. Food & Drug Administration
PR-M10-19-NI-023Oct 15, 2019
Migraine Prevention
Eli Lilly Looking to Boost Sales of Migraine Med with New Data on Emergency Room Visits
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-004Aug 01, 2019
Legal
Amgen Looking to Exit Migraine Collaboration with Novartis
Nice Insight
PAO-M04-19-NI-015Apr 10, 2019
Drug Development
EMA Committee Recommends Approval of Teva’s Anti-CGRP Treatment for Migraines
Emilie Branch
Pharma's Almanac
PAO-M02-19-NI-003Feb 06, 2019